Shorts

How New Treatment Timing Allows Fast Outpatient Care in Myeloma

Challenging the "Perfect Match" Assumption for Transplants

The Truth About Anemia Levels and Lifespan in MDS

Dr Voorhees: Identifying Ideal Candidates for SC Daratumumab

The Return to In-Person Oncology Collaboration

The Future is Still Bright for Cancer Research

Improving Progress in Cancer Research

Managing Infection with BCMA-Targeting Bispecifics

Why Use Frontline Bispecifics in Myeloma

Why "One Size" Policies Fail Rural Communities

Shifting Health Care Culture Requires Everyone Learning Together

Why Cancer Care Needs a "Both/And" Approach

Ego vs the Patient: The Hardest Medical Decision

Why Oncology is a "Black Box" for Most Primary Care Providers

The Silent Crisis in Rural Health Care

Can Quality Cancer Care Reach Rural America?

The Biggest Challenges Facing Rural Cancer Care

The Power of Perseverance: Finding Strength in Shared Journeys

Empowering Conversations: A Guide for Supporting New Diagnoses

The Best Advice From an Oncologist to a Patient

Unlocking New Possibilities in Bladder Cancer Treatment

Dr Patel: Considerations for Adjuvant Cemiplimab in CSCC

Trial Opens Up More Avenues for Treatment in Patients with Bladder Cancer

A 13-Year-Old Drug’s Persisting Power in Prostate Cancer

Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence

Pembrolizumab and Enfortumab Vedotin Demonstrate Potential in Bladder Cancer Treatment

Delaying Progression in Nonmetastatic Prostate Cancer: Insights from EMBARK

Perioperative Pembrolizumab Doubles Survival in Metastatic Bladder Cancer

The Challenge of Treating High-Risk nmCSPC

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer